Related Experiment Videos
Functional chest pain: nociception and visceral hyperalgesia
Premjit S Chahal1, Satish S C Rao
1Department of Internal Medicine, University of Iowa Carver College of Medicine Iowa City, IA 52242, USA.
Journal of Clinical Gastroenterology
|March 31, 2005
Summary
Functional chest pain is often linked to esophageal sensory dysfunction and visceral hyperalgesia. Research explores gut-brain axis roles and diagnostic tools like balloon distension for this poorly understood condition.
Area of Science:
- Gastroenterology
- Neuroscience
- Pain Medicine
Background:
- Functional chest pain is a prevalent yet poorly understood clinical condition.
- Historically attributed to psychologic factors or motility disorders, recent research highlights visceral hyperalgesia.
- The precise role of the gut-brain axis, whether central or peripheral, in visceral hypersensitivity remains under investigation.
Purpose of the Study:
- To review evolving research and clinical strategies for functional chest pain.
- To emphasize the role of esophageal sensory (afferent) neuronal dysfunction.
- To discuss diagnostic approaches and therapeutic interventions.
Main Methods:
- Review of current literature on functional chest pain.
- Discussion of diagnostic modalities including high-dose proton pump inhibitors (PPIs), upper endoscopy, esophageal pH monitoring, and esophageal balloon distension.
- Exploration of emerging diagnostic techniques like functional MRI, magnetoencephalography, and cortical evoked potentials.
Main Results:
- Visceral hyperalgesia is increasingly recognized as a key factor in functional chest pain.
- Gastroesophageal reflux disease (GERD) can be identified as a pain source through empirical therapy and diagnostic tests.
- Esophageal balloon distension is a valuable tool for diagnosing hypersensitivity.
Conclusions:
- Esophageal sensory dysfunction and visceral hyperalgesia are central to understanding functional chest pain.
- A combination of diagnostic methods is often necessary to identify underlying causes.
- Current therapeutic mainstays include high-dose PPIs and low-dose tricyclic antidepressants or trazodone, with emerging treatments showing promise.